Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.

Item

http://www.wikidata.org/entity/Q37274280

Q37274280

about

KRAS mutational analysis for colorectal cancer. Application: pharmacogenomic Three-dimensional lung tumor microenvironment modulates therapeutic compound responsiveness in vitro--implication for drug development Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study Molecular biology of lung cancer Molecular biology of lung cancer: clinical implications Optimizing the management of advanced non-small-cell lung cancer: a personal view First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer Clinical efficacy and drug resistance of anti-epidermal growth factor receptor therapy in colorectal cancer Somatic DNA mutation analysis in targeted therapy of solid tumours Personalized treatment for advanced colorectal cancer: KRAS and beyond Predictive biomarkers in precision medicine and drug development against lung cancer K-Ras Mutations in Non-Small-Cell Lung Cancer: Prognostic and Predictive Value Genomic landscape of human papillomavirus-associated cancers Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy.Molecular pathology of lung cancer: key to personalized medicine.Surgery for colorectal liver metastases: The evolution of determining prognosis Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer.Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study.EGFR gene copy number as a predictive biomarker for resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer treatment: a meta-analysis.The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK Extended RAS testing in metastatic colorectal cancer-Refining the predictive molecular biomarkers KRAS mutant allele-specific imbalance in lung adenocarcinoma Population pharmacokinetic analysis of panitumumab in patients with advanced solid tumors International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma PharmGKB summary: very important pharmacogene information for the epidermal growth factor receptor Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo A potential peptide therapeutic derived from the juxtamembrane domain of the epidermal growth factor receptor Allele specific locked nucleic acid quantitative PCR (ASLNAqPCR): an accurate and cost-effective assay to diagnose and quantify KRAS and BRAF mutation Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK Hybridization-Induced Aggregation Technology for Practical Clinical Testing: KRAS Mutation Detection in Lung and Colorectal Tumors.RAS Mutations Beyond KRAS Exon 2: A Review and Discussion of Clinical Trial Data.Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study.Experiences from treatment-predictive KRAS testing; high mutation frequency in rectal cancers from females and concurrent mutations in the same tumor.A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes.Spectrum of LKB1, EGFR, and KRAS mutations in chinese lung adenocarcinomas.East meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians.

P2860

Q21128654-ACCB748C-3BFA-4915-BE77-0A283BCE79A1 Q21132280-D6AD6BFA-061F-4571-96CF-937D157823C9 Q21142734-FEC2B38A-DC89-4002-9D11-8B53FAEDCEB1 Q24596926-BBB59CFC-C54E-4BDF-92DF-E3E9CA1FAE8E Q24606677-A1938898-F1FE-41D5-ADD2-9B206788AA74 Q24610335-85C873A5-8BEF-4B07-B96B-5EF15D1D426C Q24656144-25282975-078F-49CA-9615-B74D5F2905E0 Q26471909-AA97EFCF-D7AF-4199-887E-BAF725405735 Q26749110-8A5AA0C2-A12E-4752-A2B9-F93C6FA80D41 Q26769958-ED95DB7B-9AE4-4390-8960-7D07E70A1300 Q26770324-D15C6452-E86C-4A7C-9969-D25B7762CE8F Q26822817-54CB1791-911D-4432-B651-B86CFCD1904B Q26824536-BD8E81CA-2FAE-49CF-A1A7-898B361E5937 Q26829425-E8F4925E-BB62-4D17-833B-5A94E9452071 Q26997399-20D21DE6-63FE-4AB9-98CD-B2653939C97B Q27313799-EF6CBB77-096C-430F-B8EF-A4B293A405FE Q27691299-B2DAF0C7-2B24-4973-975F-731C7E5C182D Q27694490-B12E692C-32FB-4537-A1AE-71FEFC39FAA5 Q27851527-2296CE2D-8E44-472D-B3CC-3CA33DB7F8C4 Q27851583-EB26C831-F486-4388-A89F-50F9B97C1BBD Q27851592-9279C947-6E01-4F8F-B5E9-6FE890D9B7AA Q27852970-D3922B30-C5B4-448B-916A-5E3AE172E49D Q27852988-932DBCC3-607A-44D0-BCE0-01588CD17E62 Q28083446-A1FF02BB-0149-4BF4-B385-AD744B1ACCFA Q28087333-06651D61-C7F6-498D-AA26-44BA1B8876EF Q28242884-F048AA5E-E4DA-4043-BB52-25068D1223CD Q28257098-F41BB4F0-AE9C-44FF-AB01-E515B232D836 Q28303718-AF946866-F770-401E-A2C2-129520451AE9 Q28382921-9EC187CD-6D17-4DE6-8F6D-F60EB63EB40C Q28476362-7E09B307-E2CB-485E-B0CF-9E3D15C8C882 Q28485213-457DE512-C3BA-4ED7-B79F-2EAAE78A6372 Q28730199-DEF7500A-A188-407C-ACE9-0FA5BC52DDE6 Q28833740-A6F938F4-ABEE-4E7D-AC0A-F4E25B823527 Q30276632-B90352BE-01B8-4F6C-A899-8D99E2894C20 Q30967175-6D9EAF25-D7D1-4BC6-AB95-F9B11496CBE9 Q33407582-79650CF8-1CEA-4740-AA36-49C7757830C1 Q33510817-5078AB01-5180-4C15-BE04-B709F06C641E Q33541323-FD6679FF-DF39-4A56-97D3-B65841901576 Q33563803-EE9054F6-F928-438F-96F4-D0D133604BFC Q33579631-8E363D10-4F51-4550-B7F5-2BBB08EE58D0

P2860

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.

Item

http://www.wikidata.org/entity/Q37274280

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 17 September 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs